Semaglutide is a medicine that copies a gut hormone (GLP-1) to curb appetite and steady blood sugar. It's FDA-approved for type 2 diabetes (Ozempic, Rybelsus) and weight loss (Wegovy), and large trials show about 15% weight loss plus fewer heart problems. It has the strongest human evidence of any peptide on this site.
What is Semaglutide?
Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist that mimics the incretin hormone GLP-1. It is FDA-approved under the brand names Ozempic and Rybelsus for type 2 diabetes, and Wegovy for chronic weight management. It works by enhancing insulin secretion, suppressing glucagon, slowing gastric emptying, and reducing appetite through central nervous system signaling.
What Semaglutide Is Investigated For
Semaglutide has the deepest evidence base of any peptide for weight management and type 2 diabetes — the STEP and SUSTAIN trial programs enrolled tens of thousands of patients and consistently showed ~15-17% weight loss and strong glycemic control. The SELECT trial (2023) added proven cardiovascular benefit: a 20% reduction in major cardiac events in patients with obesity but no diabetes, making it the first weight-loss drug with demonstrated cardiovascular outcome data. The EVOKE and EVOKE+ Phase 3 Alzheimer's trials read out in Lancet May 2026 (PMID 41865758) and did NOT meet their primary cognitive endpoint — oral semaglutide 14 mg did not slow cognitive decline in early-stage symptomatic AD, though prevention-framing hypotheses about pre-symptomatic populations survive the readout. Meta-analytic signals in Parkinson's disease (30% reduced risk, PMID 41862354) and preclinical work showing GLP-1 RAs inhibit amyloid-β42 aggregation initiation (PMID 42133988) remain, but the disease-modification-in-established-AD thesis is now negative. For every use case, the evidence tier reflects the quality of human trial data — not the enthusiasm around it.
History & Discovery
Semaglutide was developed by Novo Nordisk as a structural successor to liraglutide, designed to extend GLP-1 receptor agonism from daily to once-weekly dosing. The molecule was built on the same native-GLP-1 backbone but with a longer C-18 fatty diacid side chain and a spacer that enabled much tighter albumin binding and a ~1-week half-life. The FDA approved Ozempic for type 2 diabetes in December 2017 following the SUSTAIN trial program. Rybelsus, the first oral GLP-1 agonist, won approval in September 2019 through the PIONEER program's demonstration that a co-formulation with the absorption enhancer SNAC could deliver meaningful systemic exposure. Wegovy — semaglutide at the higher 2.4 mg dose for chronic weight management — followed in June 2021 on the back of the STEP program, and the SELECT cardiovascular outcomes trial (2023) subsequently established a 20% relative reduction in major adverse cardiovascular events in patients with obesity and pre-existing CV disease, a landmark finding that extended semaglutide's indications beyond glycemic and weight endpoints.
How It Works
Semaglutide mimics a natural gut hormone (GLP-1) that tells your brain you're full after eating. It also slows down how fast food leaves your stomach and helps your pancreas release insulin more effectively when blood sugar is high.
Semaglutide activates the GLP-1 receptor, a Class B GPCR expressed in pancreatic beta cells, the hypothalamus, and brainstem. It enhances glucose-dependent insulin secretion via cAMP/PKA/Epac2 signaling in beta cells. Central GLP-1R activation in the arcuate nucleus and area postrema reduces appetite and food intake. It suppresses glucagon secretion from alpha cells, slows gastric emptying, and has direct cardiovascular protective effects. The C-18 fatty diacid modification enables non-covalent albumin binding, extending the half-life to ~1 week. A 2026 J Am Chem Soc study demonstrated that semaglutide, tirzepatide, and liraglutide directly inhibit the initiation of toxic amyloid-β42 aggregation in vitro — an interesting molecular-level finding that has not translated to established-disease benefit: the EVOKE and EVOKE+ Phase 3 primary readouts in Lancet May 2026 (PMID 41865758) failed to show cognitive-decline slowing with oral semaglutide 14 mg in early-stage symptomatic AD. Parkinson's disease signals from the 30% reduced-risk meta-analysis remain, but the Alzheimer's disease-modification thesis in symptomatic patients is now empirically negative. A companion Lancet editorial (PMID 41865757) frames the EVOKE result as closing the treatment thesis while leaving prevention-framed hypotheses in pre-symptomatic or high-metabolic-risk populations open. In parallel, the ophthalmic safety picture continues to mature — a 2026 J Clin Pharmacol systematic review and meta-analysis (PMID 42612051) synthesized the semaglutide-NAION signal supporting the 2026 NANOS/AAO consensus recommendations for shared decision-making in at-risk patients. Meanwhile the MASH generalizability story continued to accrue: a 2026 J Gastroenterol subgroup analysis (PMID 42663669) reported ESSENCE-trial outcomes in Japanese participants, extending the ethnic and geographic representativeness of the semaglutide-MASH evidence base. On the kidney side, the 52-week REMODEL mechanistic trial (Tuttle, Bjornstad et al., Nature Medicine, 1 October 2026; PMID 42823485) randomized 106 adults with type 2 diabetes and chronic kidney disease to semaglutide 1 mg weekly or placebo and did not meet its co-primary MRI endpoints: kidney oxygenation (R2*), global perfusion, and tissue inflammation (T1 mapping) were not significantly changed. Secondary outcomes pointed elsewhere — a lower renal artery resistive index, a stabilized apparent diffusion coefficient consistent with less fibrosis progression, and transcriptomic changes in glomerular endothelial cells — suggesting the kidney benefit runs through vascular resistance, fibrosis, and endothelial health rather than oxygenation or inflammation. REMODEL was built to explain how semaglutide protects the kidney, not whether it does; it does not undercut FLOW (NEJM 2024, PMID 38785209), in which semaglutide lowered the risk of the primary kidney-failure, eGFR-decline, and kidney or cardiovascular death composite by 24% over a median 3.4 years.
Evidence Snapshot
Human Clinical Evidence
Extensive. SUSTAIN, PIONEER, STEP, SOUL, and SELECT trial programs with thousands of patients. FDA-approved for multiple indications. SOUL secondary analyses (2026) extended oral semaglutide evidence to heart failure outcomes and durable multi-factor CV risk reduction over 4 years. A neuropsychiatric meta-analysis (82 studies) found GLP-1 RAs associated with 30% reduced Parkinson's risk. The EVOKE and EVOKE+ Phase 3 primary readouts (Lancet May 2026, PMID 41865758) did NOT meet the primary cognitive endpoint in early-stage symptomatic Alzheimer's disease — a major negative result in what had been the flagship GLP-1 neurodegenerative repurposing effort. The REMODEL kidney-mechanism trial (Nature Medicine, October 2026, PMID 42823485) missed its co-primary MRI endpoints but showed secondary vascular and anti-fibrotic signals; FLOW (NEJM 2024, PMID 38785209) remains the outcome evidence for kidney protection, with a 24% lower risk of its primary kidney-failure, eGFR-decline, and kidney or cardiovascular death composite. A Novo Nordisk-funded, regulator-mandated Nordic registry study presented at EASD 2026 (97,464 matched pairs) found no increase in pancreatic cancer versus other diabetes drugs.
Animal / Preclinical
Comprehensive. GLP-1 biology is one of the most studied metabolic pathways.
Mechanistic Rationale
Very strong. GLP-1 receptor signaling is thoroughly characterized.
Research Gaps & Open Questions
What the current literature has not yet settled about Semaglutide:
- 01Long-term cardiovascular and metabolic outcomes beyond the 5-year SELECT and SOUL windows — very long-term data (10+ years) on sustained use is not yet available.
- 02Optimal strategies for continuation, tapering, or cycling in the context of life-long chronic therapy — including whether periodic dose-holidays preserve efficacy and reduce side-effect burden without triggering weight regain.
- 03Muscle and bone mass preservation during rapid weight loss — body composition sub-studies suggest meaningful lean mass loss, but optimal resistance training, protein intake, and adjunctive pharmacology have not been rigorously defined.
- 04Effects in specific populations underrepresented in pivotal trials — including older adults with frailty, patients with advanced chronic kidney disease, and pediatric populations below the current age cutoffs.
- 05Neuropsychiatric signals — early post-marketing concerns about suicidal ideation have not been confirmed in large analyses, but ongoing pharmacovigilance and prospective study of mood and reward-circuit effects are warranted.
- 06Mechanism and clinical relevance of emerging signals in Alzheimer's disease and other neuropsychiatric indications — the EVOKE and EVOKE+ Phase 3 primary readouts (Lancet May 2026, PMID 41865758) did NOT meet the primary cognitive endpoint in early-stage symptomatic AD, substantially closing the disease-modification thesis in established disease. Whether prevention-framed trials in pre-symptomatic or high-metabolic-risk populations produce different results, and whether the Parkinson's disease and alcohol use disorder signals hold up in dedicated Phase 3 outcomes trials, are the remaining open questions.
- 07Regulatory environment for compounded semaglutide after February 2025 shortage delisting — a 2026 JAMA Health Forum analysis (PMID 42467450) documented persistent compounded-market activity in high-demand states following the shortage-list removal, and a 2026 Pharm Res study (PMID 42533250) characterized impurity and immunogenicity signals in follow-on and compounded GLP-1 RA products. The compounding channel has narrowed legally but has not disappeared operationally, and downstream safety consequences remain under-characterized.
Forms & Administration
Weekly SC injection (Ozempic 0.25-2mg, Wegovy 0.25-2.4mg standard or 7.2mg for BMI ≥30) or daily oral tablet (Rybelsus 3-14mg, oral Wegovy 25mg). Dose titration over 4-5 months to minimize GI side effects. All injectable peptides should only be administered under the guidance of a qualified healthcare provider. Never self-administer without clinician oversight.
Dosing & Protocols
The ranges below reflect protocols commonly discussed in the literature and by clinicians — not a prescription. Actual dosing for any individual should be determined by a qualified healthcare provider who knows the patient.
Typical Range
For Wegovy (chronic weight management), the FDA-labeled titration is 0.25 mg weekly for 4 weeks, then 0.5 mg for 4 weeks, then 1.0 mg for 4 weeks, then 1.7 mg for 4 weeks, reaching the maintenance 2.4 mg weekly dose at week 17. For Ozempic (type 2 diabetes), the schedule is 0.25 mg weekly for 4 weeks (a non-therapeutic initiation dose), then 0.5 mg, with escalation to 1.0 mg and 2.0 mg as needed for glycemic targets. Rybelsus (oral) is dosed at 3 mg daily for 30 days, then 7 mg, with optional escalation to 14 mg daily. The oral Wegovy formulation approved in late 2025 is 25 mg daily following the OASIS-4 protocol.
Frequency
Once weekly by subcutaneous injection for Ozempic and Wegovy, on the same day each week with or without regard to meals. Rybelsus and oral Wegovy are taken once daily on an empty stomach with no more than 4 ounces of plain water, followed by a 30-minute fast before food, other liquids, or other oral medications — this fasting window is necessary for SNAC-mediated absorption and is not optional.
Timing Considerations
Time of day
Once-weekly: pick the same day each week and a consistent time of day — morning or evening both work. The 5+ day half-life makes the exact hour unimportant, but consistency within a few hours helps smooth exposure.
Relative to meals
With or without food. The injection itself does not require any meal-timing relationship, though gastrointestinal side effects (nausea, early satiety) can feel more manageable when injection isn't immediately followed by a large meal.
Relative to exercise
Unrelated to training.
Cycle Length
Semaglutide is intended for indefinite chronic use in both its diabetes and obesity indications; it is not a cycled intervention. STEP-1 follow-up data show that roughly two-thirds of lost body weight is regained within a year of discontinuation, and metabolic parameters including HbA1c, blood pressure, and lipids trend back toward baseline. The operating assumption from the trial program and clinical guidelines is that the condition being treated (obesity, type 2 diabetes) is chronic, and withdrawal of therapy removes the pharmacological effect without leaving durable physiologic changes.
Protocol Notes
All injectable semaglutide products are supplied as pre-filled multi-dose pen injectors — there is no reconstitution step and no vial-and-syringe preparation required. Injection sites are the abdomen, thigh, or upper arm, and rotation across sites is advised to minimize local reactions; injection does not need to coincide with meals. The slow 16-week titration to 2.4 mg for Wegovy is driven primarily by GI tolerability: nausea, early satiety, and constipation cluster at dose transitions and typically attenuate within 1–2 weeks at each step, which is why skipping or compressing the schedule tends to worsen dropout rather than accelerate efficacy. Rybelsus represents the first and for several years only oral GLP-1 and requires the rigid fasting window described above; skipping the 30-minute wait or taking it with coffee, juice, or food substantially reduces absorption.
These doses reflect FDA-labeled protocols for specific indications. Individual dosing, titration pace, and decisions about continuation, pause, or dose reduction require clinician supervision and an individualized medical evaluation.
Timeline of Effects
Onset
Appetite suppression and reduced food reward are typically reported within the first several days of initiation, even at the sub-therapeutic 0.25 mg dose. Measurable weight loss and HbA1c improvement appear within 2–4 weeks. Full pharmacological effect requires completing the titration; STEP-1 and SUSTAIN data show that most of the weight-loss and glycemic benefit accrues during months 4–12 once the maintenance dose is reached.
Peak Effect
In STEP-1 (Wegovy, 68 weeks), mean weight loss at the 2.4 mg maintenance dose was approximately 14.9%, with the curve still sloping downward at trial end; STEP-5 extended follow-up to 104 weeks and showed weight loss plateau around 15.2% at roughly month 60 weeks. For Ozempic in SUSTAIN-6, HbA1c reductions of ~1.0–1.5 percentage points were reached by month 4–6 and sustained. The general clinical observation is that weight loss curves plateau in the 12–18 month range for most responders at a given dose.
After Discontinuation
The STEP-1 extension trial provided the clearest discontinuation data: among participants who stopped semaglutide 2.4 mg and lifestyle intervention at week 68, approximately two-thirds of lost body weight was regained within the following year, and cardiometabolic improvements (blood pressure, HbA1c, lipid markers) largely reverted toward baseline. The kinetics reflect both pharmacology (the ~1-week half-life means the drug clears within roughly 5 weeks of the last dose) and the underlying biology of obesity as a chronic condition in which adipose set-points reassert once the pharmacological signal is removed.
Monitoring & Measurement
Bloodwork & Labs
- •HbA1c — the primary glycemic endpoint; rechecked every 3 months
- •Fasting glucose and fasting insulin (HOMA-IR) — pairs well with HbA1c for insulin-resistance tracking
- •Lipid panel (total cholesterol, LDL, HDL, triglycerides) — triglycerides typically respond within 12 weeks
- •ALT and AST — NAFLD-adjacent; often improve as weight drops
- •Lipase and amylase at baseline — pancreatitis is rare but real, and baseline values anchor any later rise
Functional & Performance Tests
- •Body weight (same scale, same time of day, weekly at home)
- •Waist circumference — more sensitive to visceral fat than scale weight alone
- •Home blood pressure cuff — systolic typically falls 4–6 mmHg
- •Resting heart rate (wearable) — expect a modest rise of 2–4 bpm
- •DEXA scan if accessible — tracks lean-mass preservation, which is the quality-of-loss question
When to Test
Baseline, 12 weeks, 24 weeks, then annually while on therapy. Weight and waist weekly at home.
Interpretation & Notes
The STEP and SUSTAIN trials set clear expectations: roughly 15% body weight loss and a 1.5–2.0 point HbA1c drop by week 68 at 2.4 mg. The most useful early checkpoint is 5% weight loss by week 16 — that's the clinical 'responder' threshold, and patients who miss it rarely catch up without dose changes. Lean-mass loss averages 25–40% of total weight lost, so the real 6-month question isn't 'did I lose weight' but 'did I lose the right weight' — DEXA, resistance training, and adequate protein are the levers. If lipase exceeds roughly 3x the upper limit of reference or you develop persistent upper-abdominal pain, stop and see a clinician. Panels are widely available direct-to-consumer via LabCorp, Quest, Marek Health, and Ulta Lab Tests; interpret results with a clinician before adjusting dose.
Common Questions
How much weight can you lose on semaglutide?
Clinical trials show average weight loss of 15-17% of body weight over 68 weeks with Wegovy (2.4mg weekly). Individual results vary, and weight regain is common after discontinuation.
Is semaglutide a peptide?
Yes. Semaglutide is a 31-amino acid peptide analogue of human GLP-1, modified with a C-18 fatty diacid chain for albumin binding that extends its half-life to approximately 1 week.
What is the difference between Ozempic, Wegovy, and Rybelsus?
All three are semaglutide, just packaged for different indications and routes. Ozempic is the once-weekly subcutaneous injection FDA-approved in 2017 for type 2 diabetes (0.25–2 mg). Wegovy is the same molecule at the higher 2.4 mg once-weekly dose, approved in 2021 for chronic weight management, and now also available as a 25 mg daily oral pill from late 2025. Rybelsus is the original oral formulation approved in 2019 for type 2 diabetes (3–14 mg daily), and it relies on the absorption enhancer SNAC plus a strict empty-stomach dosing window.
Does semaglutide reduce heart attack and stroke risk?
Yes — this is one of its strongest clinical signals beyond weight and glucose. The SELECT trial (2023) showed a 20% relative reduction in major adverse cardiovascular events in patients with obesity and established cardiovascular disease but no diabetes, leading to a formal FDA indication for cardiovascular risk reduction in this group. The SOUL trial (2025) extended the cardiovascular benefit to oral semaglutide in high-risk type 2 diabetes, with a 14% MACE reduction over nearly 4 years.
Who Semaglutide Is NOT For
- •Personal or family history of medullary thyroid carcinoma (MTC) — boxed warning based on rodent C-cell tumor findings; human relevance is debated but the contraindication is absolute per labeling.
- •Multiple Endocrine Neoplasia syndrome type 2 (MEN2) — same mechanistic concern as MTC, given its genetic link to medullary thyroid cancer risk.
- •Prior serious hypersensitivity reaction (anaphylaxis, angioedema) to semaglutide or any component of the formulation.
- •Active pancreatitis or history of recurrent pancreatitis — GLP-1 agonists have been associated with rare acute pancreatitis signals in post-marketing surveillance.
- •Pregnancy — animal reproductive toxicity data and the absence of human pregnancy safety data make continuation contraindicated; labeling advises discontinuation at least 2 months before a planned pregnancy given the drug's long half-life.
- •Breastfeeding — transfer into human milk has not been adequately characterized; risk-benefit should be individualized with the prescribing clinician.
- •Severe gastroparesis or other significant gastrointestinal motility disorders — GLP-1-induced delayed gastric emptying can worsen symptoms and precipitate obstruction in severe cases.
- •Pediatric use below the approved age cutoffs — Wegovy is approved for adolescents 12 and older, Ozempic is not approved under 18, and Rybelsus is not approved under 18.
Drug & Supplement Interactions
The two most clinically important interaction domains are hypoglycemia risk and altered oral drug absorption. When semaglutide is combined with insulin or insulin secretagogues (sulfonylureas, meglitinides), hypoglycemia risk rises substantially, and downward titration of the concomitant agent is typically required at semaglutide initiation and each dose escalation. Because semaglutide slows gastric emptying, the absorption rate and peak concentrations of many orally administered drugs can be altered — this is particularly relevant for narrow-therapeutic-index agents including warfarin (INR monitoring advised after dose changes), levothyroxine (TSH should be rechecked after titration), oral contraceptives (effectiveness is not expected to be reduced but labeling recommends awareness), and orally administered antibiotics and antiepileptics. Rybelsus' reliance on an empty-stomach window introduces additional practical interactions: taking other oral medications within the 30-minute fasting window can impair both Rybelsus absorption and the other medication's absorption. Patients on any chronic oral regimen should review timing and monitoring requirements with their prescribing clinician; post-marketing signals for rare outcomes like suicidal ideation and diabetic retinopathy progression are being tracked but are not currently established as contraindications.
Safety Profile
Common Side Effects
Cautions
- • Contraindicated in personal/family history of medullary thyroid carcinoma or MEN2
- • Risk of pancreatitis
- • May cause gallbladder problems
- • Not for use with other GLP-1 agonists
- • Small possible increased risk of non-arteritic anterior ischemic optic neuropathy (NAION) — 2026 NANOS/AAO consensus advises shared decision-making in patients with prior NAION or anatomic optic-nerve crowding
What We Don't Know
Long-term effects beyond 2 years of use, effects on muscle mass during weight loss, and optimal duration of therapy are still being studied. On pancreatic cancer, a regulator-mandated, Novo Nordisk-funded registry study from Denmark, Sweden, and Norway (NCT04572165; presented at EASD 2026, not yet peer-reviewed) compared 97,464 people with type 2 diabetes starting semaglutide against matched new users of insulin, sulfonylureas, or SGLT2 inhibitors and found no increased risk (131 vs 123 cases; pooled HR 0.91, 95% CI 0.71–1.16) and no dose-response — reassuring, but mean follow-up after a 1-year lag was under two years, too short to rule out a slow-developing cancer signal.
Legal Status
United States
Semaglutide is FDA-approved as Ozempic (2017) and Rybelsus (2019) for type 2 diabetes, as Wegovy (2021) for chronic weight management in adults and adolescents aged 12+ with obesity, and as of late 2025 in an oral Wegovy formulation following OASIS-4. It additionally carries an FDA indication for reducing MACE in adults with established cardiovascular disease and obesity/overweight (SELECT, 2024). On January 28, 2025, Ozempic was approved to reduce the risk of sustained eGFR decline, end-stage kidney disease, and cardiovascular death in adults with type 2 diabetes and chronic kidney disease, based on the FLOW trial. Rybelsus's label now also carries a MACE risk-reduction indication for adults with type 2 diabetes at high cardiovascular risk (SOUL). No generic semaglutide has final FDA approval: Apotex received tentative approval for a generic semaglutide injection on April 7, 2026, which does not allow it to be marketed, and the patent landscape protects Novo Nordisk's exclusivity into the late 2020s. Compounded semaglutide was marketed heavily while semaglutide injection was on FDA's shortage list (2022 to February 2025). FDA declared that shortage resolved on February 21, 2025, and enforcement discretion ended April 22, 2025 for 503A pharmacies and May 22, 2025 for 503B outsourcing facilities, after a federal court declined on April 24, 2025 to block the decision. Since then, a 503A pharmacy may not regularly compound copies of the approved products unless a prescriber documents a significant difference for an individual patient, and 503B outsourcing facilities cannot compound semaglutide from bulk drug substance because it is neither in shortage nor on the 503B bulks list. In 2026 FDA used semaglutide plus vitamin B12 as its example of a combination that can still be essentially a copy (April 1), proposed excluding semaglutide, tirzepatide, and liraglutide from the 503B bulks list (April 30; no final decision had been published at the time of this update), and named Empower Pharmacy's semaglutide/cyanocobalamin product as essentially a copy of an FDA-approved drug in a September 18 warning letter.
International
Semaglutide is authorized by the EMA (Ozempic, Rybelsus, Wegovy), the UK MHRA, Health Canada, and Australia's TGA for parallel indications. Availability and reimbursement vary considerably: NHS coverage in the UK for Wegovy is restricted by NICE criteria, and several European payers have tightened obesity-indication coverage relative to diabetes coverage. Compounded and grey-market sourcing is widespread but legally precarious in most jurisdictions.
Sports & Competition
Semaglutide is not named on the WADA Prohibited List (the 2026 list, or the 2027 list that takes effect January 1, 2027), and neither is any GLP-1 receptor agonist. Because semaglutide is an approved medicine, WADA's S0 'non-approved substances' category does not apply, so no Therapeutic Use Exemption is needed. Athletes in weight-category sports should still check their own federation's rules before use.
Regulatory status changes over time. Verify current local rules with a qualified professional.
Myths & Misconceptions
Myth
Ozempic is just an easy way out — it's 'cheating' at weight loss.
Reality
Obesity is a chronic disease with strong neuroendocrine drivers; the GLP-1 system is a native appetite-regulation pathway that is dysregulated in many people with obesity. Semaglutide restores physiological satiety signaling rather than bypassing effort. The SELECT trial further demonstrated a 20% relative reduction in major cardiovascular events independent of any moral framing of the weight loss, which is the kind of hard outcome that lifestyle intervention alone rarely achieves at scale.
Myth
You lose the weight back the moment you stop, so it's not worth taking.
Reality
The weight regain after discontinuation is real — STEP-1 follow-up showed roughly two-thirds regain within a year — but the framing is upside-down. Most chronic conditions return when their treatment is stopped; insulin, antihypertensives, and statins behave the same way. The question isn't whether benefits persist off-drug but whether the benefits while on-drug (weight loss, glycemic control, CV risk reduction) justify chronic therapy for the patient in question.
Myth
Ozempic destroys your muscle mass.
Reality
All rapid weight loss — dietary, surgical, or pharmacological — includes lean mass loss, and semaglutide is no exception; body composition sub-studies typically show roughly 25–40% of lost weight comes from lean tissue. What is not established is that GLP-1 agonists cause disproportionate muscle loss beyond what comparable weight loss by other means produces. Resistance training and adequate protein intake during treatment are standard mitigation strategies and are broadly recommended by obesity medicine societies.
Myth
Compounded semaglutide is the same drug as Ozempic or Wegovy.
Reality
Compounded semaglutide is not FDA-approved, is not bioequivalence-tested against the branded products, and its active pharmaceutical ingredient may include semaglutide salts (sodium, acetate) that are structurally distinct from the base peptide in the approved drugs. Quality, potency, and sterility vary by pharmacy. Since FDA declared the shortage resolved on February 21, 2025, much ongoing compounding falls outside the narrow legal 503A pathway, and adding vitamin B12 does not change that: FDA has said a semaglutide/B12 product can still be essentially a copy. That adds regulatory risk on top of clinical risk.
Myth
GLP-1 agonists cause thyroid cancer in humans.
Reality
The thyroid C-cell tumor signal comes from rodent carcinogenicity studies, and human relevance remains scientifically contested. Large pharmacovigilance analyses and meta-analyses to date have not established a causal link between semaglutide and medullary thyroid carcinoma in humans. The contraindication in personal/family history of MTC and MEN2 is a conservative precaution, not a confirmed causal relationship — but it is clinically binding.
Published Research
54 studiesEffects of semaglutide on kidney disease in type 2 diabetes: a randomized placebo-controlled trial.
Semaglutide in Japanese participants with metabolic dysfunction-associated steatohepatitis: a subgroup analysis of the ESSENCE trial.
Semaglutide-Induced Nonarteritic Anterior Ischemic Optic Neuropathy: A Systematic Review and Meta-Analysis.
Impurities and Potential Immunogenicity Associated With Follow-on and Compounded Glucagon-like Peptide-1 Receptor Agonists.
Postshortage Compounded GLP-1 RA Market in 2 States With Potentially High Demand.
Glucagon-Like Peptide-1 Receptor Agonists Inhibit the Initiation of Toxic Amyloid-β42 Aggregation
Glucagon-Like Peptide-1 Receptor Agonists and the Risk of Non-Arteritic Anterior Ischemic Optic Neuropathy: A Consensus Statement by the North American Neuro-Ophthalmology Society and the American Academy of Ophthalmology
NANOS/AAO joint consensus statement (Ophthalmology 2026) on the GLP-1 RA / NAION safety signal — concludes the magnitude of risk is low but advises shared decision-making, particularly for patients with prior NAION or vascular crowding of the optic nerve.
Oral Semaglutide and Change in Cardiovascular Risk Factors in High-Risk Type 2 Diabetes: A Post Hoc Secondary Analysis of the SOUL Randomized Clinical Trial (Mulvagh et al., JAMA Cardiol 2026)
Efficacy and safety of oral semaglutide 14 mg (flexible dose) in early-stage symptomatic Alzheimer's disease (evoke and evoke+): two phase 3, randomised, placebo-controlled trials.
EVOKE and EVOKE+ Phase 3 primary readout in Lancet May 2026 — oral semaglutide 14 mg did NOT meet the primary cognitive endpoint in early-stage symptomatic Alzheimer's disease. The largest and most-watched GLP-1 repurposing trial in neurodegeneration; the negative result substantially closes the disease-modification-in-established-AD thesis, though pre-symptomatic prevention framing survives. Reshapes every prior discussion of semaglutide's neurodegenerative use case.
Semaglutide for Alzheimer's disease after evoke and evoke.
Effect of Glucagon-Like-Peptide-1 Receptor Agonists (GLP-1 RA) on Neuropsychiatric Outcomes: A Systematic Review and Meta-Analysis (Choudhury et al., Clin Ther 2026)
Meta-analysis of 82 randomized and observational studies finding GLP-1 receptor agonists associated with 30% reduced Parkinson's disease risk (HR 0.70) and potential benefit in binge eating disorder. Evidence for dementia risk reduction was mixed, and certainty was mostly low to very low.
Ocular complications from glucagon-like peptide-1 receptor agonists: Clinical evidence, potential mechanisms, and clinical recommendations (Wu & Chen, J Chin Med Assoc 2026)
Efficacy and Safety of Cagrilintide and Cagrisema Versus Semaglutide as Anti-Obesity Medications: A Systematic Review, Meta-Analysis and Meta-Regression (Ahmed et al., Diabetes Obes Metab 2026)
Oral Semaglutide and Heart Failure Outcomes in Persons With Type 2 Diabetes: A Secondary Analysis of the SOUL Randomized Clinical Trial (Pop-Busui et al., JAMA Intern Med 2026)
Secondary analysis of the SOUL trial extending oral semaglutide's cardiovascular evidence specifically to heart failure outcomes in type 2 diabetes patients.
Oral Semaglutide at a Dose of 25 mg in Adults with Overweight or Obesity
The OASIS 4 trial showed oral semaglutide 25mg achieved 16.6% weight loss — comparable to injectable Wegovy — leading to FDA approval of the oral Wegovy pill in late 2025.
Semaglutide in Adults with Type 1 Diabetes and Obesity
Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity
Cagrilintide-Semaglutide in Adults with Overweight or Obesity and Type 2 Diabetes
Phase 3 Trial of Semaglutide in Metabolic Dysfunction-Associated Steatohepatitis
Semaglutide achieved MASH resolution without worsening fibrosis in a significantly greater proportion of patients than placebo, establishing it as a potential first-line pharmacotherapy for metabolic liver disease.
Discontinuing glucagon-like peptide-1 receptor agonists and body habitus: A systematic review and meta-analysis
Semaglutide and walking capacity in people with symptomatic peripheral artery disease and type 2 diabetes (STRIDE): a phase 3b, double-blind, randomised, placebo-controlled trial
Oral Semaglutide and Cardiovascular Outcomes in High-Risk Type 2 Diabetes
The SOUL trial (n=9,650) demonstrated that oral semaglutide reduced major adverse cardiovascular events by 14% in patients with type 2 diabetes at high cardiovascular risk.
Cardiovascular and Kidney Outcomes and Mortality With Long-Acting Injectable and Oral Glucagon-Like Peptide 1 Receptor Agonists in Individuals With Type 2 Diabetes: A Systematic Review and Meta-analysis of Randomized Trials
Oral Semaglutide and Cardiovascular Outcomes in People With Type 2 Diabetes, According to SGLT2i Use: Prespecified Analyses of the SOUL Randomized Trial
Once-Weekly Semaglutide in Adults With Alcohol Use Disorder: A Randomized Clinical Trial
Hendershot et al. (JAMA Psychiatry 2025): a 9-week Phase 2 trial in 48 non-treatment-seeking adults with alcohol use disorder, using low doses (up to 1.0 mg weekly). Semaglutide reduced alcohol consumed in a laboratory self-administration test (the primary outcome), drinks per drinking day, and weekly craving. It did not change the number of drinking days or average drinks per day. Early evidence that justifies larger trials, not proof of benefit.
evoke and evoke+: design of two large-scale, double-blind, placebo-controlled, phase 3 studies evaluating efficacy, safety, and tolerability of semaglutide in early-stage symptomatic Alzheimer's disease
Design paper for two landmark Phase 3 trials testing semaglutide as a disease-modifying treatment for early Alzheimer's disease — one of the most ambitious GLP-1 repurposing efforts.
Effect of glucagon-like peptide-1 receptor agonists and co-agonists on body composition: Systematic review and network meta-analysis
Once-Weekly Semaglutide in Persons with Obesity and Knee Osteoarthritis
Semaglutide in patients with overweight or obesity and chronic kidney disease without diabetes: a randomized double-blind placebo-controlled clinical trial
Seven glucagon-like peptide-1 receptor agonists and polyagonists for weight loss in patients with obesity or overweight: an updated systematic review and network meta-analysis of randomized controlled trials
Evaluating the safety profile of semaglutide: an updated meta-analysis
Clinical Pharmacokinetics of Semaglutide: A Systematic Review
Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes.
FLOW (Perkovic et al., NEJM 2024): 3,533 adults with type 2 diabetes and chronic kidney disease, semaglutide 1.0 mg weekly vs placebo, stopped early for efficacy after a median 3.4 years. The primary kidney-failure, eGFR-decline, and kidney or cardiovascular death composite fell 24% (HR 0.76), cardiovascular death 29% (HR 0.71), and all-cause death 20% (HR 0.80). The basis for Ozempic's January 2025 kidney indication.
Long-Term Efficacy and Safety of Once-Weekly Semaglutide for Weight Loss in Patients Without Diabetes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
Assessment of Thyroid Carcinogenic Risk and Safety Profile of GLP1-RA Semaglutide (Ozempic) Therapy for Diabetes Mellitus and Obesity: A Systematic Literature Review
Subcutaneously administered tirzepatide vs semaglutide for adults with type 2 diabetes: a systematic review and network meta-analysis of randomised controlled trials
Pharmacotherapy for adults with overweight and obesity: a systematic review and network meta-analysis of randomised controlled trials
Comparative effectiveness of GLP-1 receptor agonists on glycaemic control, body weight, and lipid profile for type 2 diabetes: systematic review and network meta-analysis
Efficacy and Safety of Glucagon-Like Peptide-1 Receptor Agonists on Body Weight and Cardiometabolic Parameters in Individuals With Obesity and Without Diabetes: A Systematic Review and Meta-Analysis
Efficacy and safety of semaglutide 2.4 mg for weight loss in overweight or obese adults without diabetes: An updated systematic review and meta-analysis including the 2-year STEP 5 trial
The Weight-loss Effect of GLP-1RAs Glucagon-Like Peptide-1 Receptor Agonists in Non-diabetic Individuals with Overweight or Obesity: A Systematic Review with Meta-Analysis and Trial Sequential Analysis of Randomized Controlled Trials
Efficacy and Safety of Semaglutide for Weight Loss in Obesity Without Diabetes: A Systematic Review and Meta-Analysis
Semaglutide for the treatment of overweight and obesity: A review
Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial.
Once-Weekly Semaglutide in Adults with Overweight or Obesity.
The landmark STEP 1 trial (n=1,961) showed semaglutide 2.4mg produced 14.9% mean weight loss vs 2.4% with placebo at 68 weeks — the pivotal trial for Wegovy's FDA approval.
Comparative Effectiveness of Glucose-Lowering Drugs for Type 2 Diabetes: A Systematic Review and Network Meta-analysis
Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials
Epidemiological Assessment of the Risk for Pancreatic Cancer Associated With the Use of Semaglutide in Patients With Type 2 Diabetes - A Cohort Study Based on Nordic Registry Data (NCT04572165)
Regulator-mandated study finds no link between semaglutide use and pancreatic cancer (EASD 2026 presentation coverage)
FDA approves Ozempic (semaglutide) as the only GLP-1 RA to reduce the risk of worsening kidney disease and cardiovascular death in adults with type 2 diabetes and chronic kidney disease (Novo Nordisk, January 28, 2025)
OZEMPIC (semaglutide) injection prescribing information (DailyMed)
FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize (semaglutide shortage resolution, February 21, 2025, and enforcement timelines)
FDA warning letter to Empower Clinic Services, LLC dba Empower Pharmacy (September 18, 2026)
Drugs@FDA: ANDA 220314, semaglutide injection (Apotex; tentative approval April 7, 2026)
Popular Stacks Including Semaglutide
Semaglutide + B12 (Compounded Semaglutide)
The most commonly prescribed compounded semaglutide formulation for weight loss. Pairs GLP-1 therapy with vitamin B12 to address nutrient absorption concerns and support energy during caloric restriction. Often includes glycine.
CagriSema / CagriTriz / CagriReta (Cagrilintide + GLP-1 Agonist)
A family of weekly injectable obesity stacks that pair the long-acting amylin analog cagrilintide with a GLP-1 receptor agonist — semaglutide (CagriSema), tirzepatide (CagriTriz), or retatrutide (CagriReta). Only CagriSema has completed pivotal clinical trials; the other two are conceptual compounded or investigational combinations.
Quick Facts
- Class
- GLP-1 Receptor Agonist
- Tier
- S
- Evidence
- Strong
- Safety
- Well-Studied
- Updated
- Oct 2026
- Citations
- 54PubMed
Also known as
Tags
Peptide Families
Related Goals
Evidence Score
Clinical Trials
View Clinical TrialsLinks to ClinicalTrials.gov for reference. Listing does not imply endorsement.